Product manufactured by Sandoz Inc

Application Nr Approved Date Route Status External Links
NDA021284 2014-10-27 Oral DISCN Google , Wikipedia , PubMed , DailyMed , Raw OpenFDA , ECHA , ToxNet , JECFA , FAO , 21 CFR

Indications and Purposes

Indications And Usage Methylphenidate Hydrochloride Extended-Release Capsules Are Indicated For The Treatment Of Attention Deficit Hyperactivity Disorder (adhd). The Efficacy Of Methylphenidate Hydrochloride Extended-Release Capsules In The Treatment Of Adhd Was Established In 1 Controlled Trial Of Children Aged 6 To 12 Who Met Dsm-Iv Criteria For Adhd (see Clinical Pharmacology). A Diagnosis Of Attention Deficit Hyperactivity Disorder (adhd; Dsm-Iv) Implies The Presence Of Hyperactive-Impulsive Or Inattentive Symptoms That Caused Impairment And Were Present Before Age 7 Years. The Symptoms Must Cause Clinically Significant Impairment, E.g., In Social, Academic, Or Occupational Functioning, And Be Present In 2 Or More Settings, E.g., School (or Work) And At Home. The Symptoms Must Not Be Better Accounted For By Another Mental Disorder. For The Inattentive Type, At Least 6 Of The Following Symptoms Must Have Persisted For At Least 6 Months: Lack Of Attention To Details/careless Mistakes; Lack Of Sustained Attention; Poor Listener; Failure To Follow Through On Tasks; Poor Organization; Avoids Tasks Requiring Sustained Mental Effort; Loses Things; Easily Distracted; Forgetful. For The Hyperactive-Impulsive Type, At Least 6 Of The Following Symptoms Must Have Persisted For At Least 6 Months: Fidgeting/squirming; Leaving Seat; Inappropriate Running/climbing; Difficulty With Quiet Activities; “on The Go;” Excessive Talking; Blurting Answers; Can’t Wait Turn; Intrusive. The Combined Types Requires Both Inattentive And Hyperactive-Impulsive Criteria To Be Met. Special Diagnostic Considerations Specific Etiology Of This Syndrome Is Unknown, And There Is No Single Diagnostic Test. Adequate Diagnosis Requires The Use Not Only Of Medical But Of Special Psychological, Educational, And Social Resources. Learning May Or May Not Be Impaired. The Diagnosis Must Be Based Upon A Complete History And Evaluation Of The Child And Not Solely On The Presence Of The Required Number Of Dsm-Iv Characteristics. Need For Comprehensive Treatment Program Methylphenidate Hydrochloride Extended-Release Capsules Are Indicated As An Integral Part Of A Total Treatment Program For Adhd That May Include Other Measures (psychological, Educational, Social) For Patients With This Syndrome. Drug Treatment May Not Be Indicated For All Children With This Syndrome. Stimulants Are Not Intended For Use In The Child Who Exhibits Symptoms Secondary To Environmental Factors And/or Other Primary Psychiatric Disorders, Including Psychosis. Appropriate Educational Placement Is Essential And Psychosocial Intervention Is Often Helpful. When Remedial Measures Alone Are Insufficient, The Decision To Prescribe Stimulant Medication Will Depend Upon The Physician’s Assessment Of The Chronicity And Severity Of The Child’s Symptoms. Long-Term Use The Effectiveness Of Methylphenidate Hydrochloride Extended-Release Capsules For Long-Term Use, I.e., For More Than 2 Weeks, Has Not Been Systematically Evaluated In Controlled Trials. Therefore, The Physician Who Elects To Use Methylphenidate Hydrochloride Extended-Release Capsules For Extended Periods Should Periodically Re-Evaluate The Long-Term Usefulness Of The Drug For The Individual Patient (see Dosage And Administration).

All Formulated Excipients (7 Total)

Name Structure Kind Function Status
1. Ammonio Methacrylate Copolymer AMMONIO METHACRYLATE COPOLYMER Unresolved
2. Gelatin GELATIN Unresolved
3. Methacrylic Acid Copolymer METHACRYLIC ACID COPOLYMER Unresolved
4. Polyethylene Glycols POLYETHYLENE GLYCOLS Unresolved
5. Talc TALC Unresolved DYE-Dye GRAS-Generally recognized as safe.
6. Titanium Dioxide TITANIUM DIOXIDE Unresolved DYE-Dye
7. Triethyl Citrate TRIETHYL CITRATE Molecular MISC-Miscellaneous GRAS-Generally recognized as safe.

Active Ingredients ( 1 Total)

Name Structure ZINC ID(s)
1. Methylphenidate Hydrochloride METHYLPHENIDATE HYDROCHLORIDE ZINC2522648